Cargando…
Substrate and product analogues as human O-GlcNAc transferase inhibitors
Protein glycosylation on serine/threonine residues with N-acetylglucosamine (O-GlcNAc) is a dynamic, inducible and abundant post-translational modification. It is thought to regulate many cellular processes and there are examples of interplay between O-GlcNAc and protein phosphorylation. In metazoa,...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040809/ https://www.ncbi.nlm.nih.gov/pubmed/20640461 http://dx.doi.org/10.1007/s00726-010-0688-y |
_version_ | 1782198379501060096 |
---|---|
author | Dorfmueller, Helge C. Borodkin, Vladimir S. Blair, David E. Pathak, Shalini Navratilova, Iva van Aalten, Daan M. F. |
author_facet | Dorfmueller, Helge C. Borodkin, Vladimir S. Blair, David E. Pathak, Shalini Navratilova, Iva van Aalten, Daan M. F. |
author_sort | Dorfmueller, Helge C. |
collection | PubMed |
description | Protein glycosylation on serine/threonine residues with N-acetylglucosamine (O-GlcNAc) is a dynamic, inducible and abundant post-translational modification. It is thought to regulate many cellular processes and there are examples of interplay between O-GlcNAc and protein phosphorylation. In metazoa, a single, highly conserved and essential gene encodes the O-GlcNAc transferase (OGT) that transfers GlcNAc onto substrate proteins using UDP–GlcNAc as the sugar donor. Specific inhibitors of human OGT would be useful tools to probe the role of this post-translational modification in regulating processes in the living cell. Here, we describe the synthesis of novel UDP–GlcNAc/UDP analogues and evaluate their inhibitory properties and structural binding modes in vitro alongside alloxan, a previously reported weak OGT inhibitor. While the novel analogues are not active on living cells, they inhibit the enzyme in the micromolar range and together with the structural data provide useful templates for further optimisation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00726-010-0688-y) contains supplementary material, which is available to authorized users. |
format | Text |
id | pubmed-3040809 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-30408092011-03-29 Substrate and product analogues as human O-GlcNAc transferase inhibitors Dorfmueller, Helge C. Borodkin, Vladimir S. Blair, David E. Pathak, Shalini Navratilova, Iva van Aalten, Daan M. F. Amino Acids Original Article Protein glycosylation on serine/threonine residues with N-acetylglucosamine (O-GlcNAc) is a dynamic, inducible and abundant post-translational modification. It is thought to regulate many cellular processes and there are examples of interplay between O-GlcNAc and protein phosphorylation. In metazoa, a single, highly conserved and essential gene encodes the O-GlcNAc transferase (OGT) that transfers GlcNAc onto substrate proteins using UDP–GlcNAc as the sugar donor. Specific inhibitors of human OGT would be useful tools to probe the role of this post-translational modification in regulating processes in the living cell. Here, we describe the synthesis of novel UDP–GlcNAc/UDP analogues and evaluate their inhibitory properties and structural binding modes in vitro alongside alloxan, a previously reported weak OGT inhibitor. While the novel analogues are not active on living cells, they inhibit the enzyme in the micromolar range and together with the structural data provide useful templates for further optimisation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00726-010-0688-y) contains supplementary material, which is available to authorized users. Springer Vienna 2010-07-17 2011 /pmc/articles/PMC3040809/ /pubmed/20640461 http://dx.doi.org/10.1007/s00726-010-0688-y Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Original Article Dorfmueller, Helge C. Borodkin, Vladimir S. Blair, David E. Pathak, Shalini Navratilova, Iva van Aalten, Daan M. F. Substrate and product analogues as human O-GlcNAc transferase inhibitors |
title | Substrate and product analogues as human O-GlcNAc transferase inhibitors |
title_full | Substrate and product analogues as human O-GlcNAc transferase inhibitors |
title_fullStr | Substrate and product analogues as human O-GlcNAc transferase inhibitors |
title_full_unstemmed | Substrate and product analogues as human O-GlcNAc transferase inhibitors |
title_short | Substrate and product analogues as human O-GlcNAc transferase inhibitors |
title_sort | substrate and product analogues as human o-glcnac transferase inhibitors |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040809/ https://www.ncbi.nlm.nih.gov/pubmed/20640461 http://dx.doi.org/10.1007/s00726-010-0688-y |
work_keys_str_mv | AT dorfmuellerhelgec substrateandproductanaloguesashumanoglcnactransferaseinhibitors AT borodkinvladimirs substrateandproductanaloguesashumanoglcnactransferaseinhibitors AT blairdavide substrateandproductanaloguesashumanoglcnactransferaseinhibitors AT pathakshalini substrateandproductanaloguesashumanoglcnactransferaseinhibitors AT navratilovaiva substrateandproductanaloguesashumanoglcnactransferaseinhibitors AT vanaaltendaanmf substrateandproductanaloguesashumanoglcnactransferaseinhibitors |